FDA OK's Medtronic's high-energy HF (heart failure) device:
This article was originally published in Clinica
Medtronic has gained US approval to sell the latest product in its line of devices for treating heart failure (HF). The InSync Maximo cardiac resynchronisation therapy defibrillator (CRT-D) stops lethally fast heart rhythms using a combination of high-output defibrillation energy (35 joules) and what the firm claims is the industry's fastest charge times - ie the number of seconds between the time the device detects an abnormally fast rhythm and the moment it is ready to deliver defibrillation therapy.
You may also be interested in...
Diagnostics company Bodysphere had to retract an announcement that it had received an emergency use authorization from the US FDA for a COVID-19 serologic test. See why Bethany Hills, an attorney with law firm Morrison & Foerster, says this may be a cautionary tale for other manufacturers.
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.